Congratulations to Professor Craig Crews

August 1, 2012

Congratulations to Professor Craig Crews on the FDA’s recent approval of Kyprolis (carfilzomib) for the treatment of relapsed, refractory multiple myeloma - a particularly deadly form of cancer that originates from certain white blood cells. The approval of Kyprolis represents the culmination of over a decade’s worth of work, which emerged from the Crews lab’s discovery that the natural product epoxomicin could function as a highly potent, selective inhibitor of the proteasome. Kyprolis, a chemical derivative of epoxomicin first prepared in the Crews lab, earned FDA approval on July 20, and has been available for patients in the U.S. since August 1. Congratulations to Professor Crews, and all past and present members of the Crews lab, who have contributed to this exciting advance!